Loading...
Loading...
ONCY| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 123.0K |
| Gross Profit | -123.0K |
| Operating Expense | 8,603.0K |
| Operating I/L | -8,726.0K |
| Other Income/Expense | 1,832.0K |
| Interest Income | 446.0K |
| Pretax | -6,894.0K |
| Income Tax Expense | 79.7K |
| Net Income/Loss | -6,894.0K |
Oncolytics Biotech Inc. is a biopharmaceutical company specializing in the development of cancer treatment products. Its primary focus is on pelareorep, an immunotherapeutic agent for solid tumors and hematological malignancies. The company has a co-development agreement with Merck KGaA and Pfizer Inc. to develop pelareorep in combination with paclitaxel and avelumab for the treatment of metastatic breast cancer. Oncolytics Biotech Inc. generates revenue through the development and commercialization of its pharmaceutical products, particularly pelareorep, aimed at addressing unmet medical needs in the field of oncology.
